Insulin Icodec – the once a week long acting insulin from Novo Nordisk was reported by Tim Street for Diabettech.com, 18 June 2020. 

Novo Nordisk announced that at the end of their phase 2 trial, the once weekly insulin, Icodec had performed AS WELL AS LANTUS in their 26 week trial with 247 people with Type 2 Diabetes. 

Insulin Icodec is an investigational, long-acting basal insulin analogue with a half-life of 196 hours. Yes, that’s a half life of more than 8 days. It has also gone under the name IA287 in the past, and other trials (including one in people with Type 1) can be found with this name.

Once injected, insulin icodec binds strongly but reversibly to albumin, (a similar behaviour occurs in both Detemir and Degludec, but not to the same extent). This results in a continuous, slow and steady reduction of blood sugar over the week. The injection volume of once-weekly insulin icodec is equivalent to daily insulin glargine U100 due to the concentrated formulation that it uses.

Read more:  Insulin Icodec – the once a week long acting insulin from Novo Nordisk


Precision Nutrition—the Answer to “What to Eat to Stay Healthy” was reported by Griffin P. Rodgers, MD and Francis S. Collins, MD, PhD for JAMANetwork.com, 7 August 2020.